OR WAIT null SECS
October 21, 2025
Article
A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.
October 17, 2025
Video
Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.
October 15, 2025
An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.
October 13, 2025
Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.
October 07, 2025
The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.
October 06, 2025
Read about groundbreaking FDA decisions, exciting new heart failure research, and more.
October 03, 2025
This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.
September 28, 2025
Aficamten shows superior exercise capacity improvements over metoprolol for patients with oHCM.
New 96-week data reveals aficamten's significant benefits for patients with nonobstructive hypertrophic cardiomyopathy.
Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.
